RAAG12 carbohydrate antigen (RAAG12)

RAAG12 is a primate-restricted N-linked carbohydrate antigen present on multiple membrane-associated proteins. It is highly expressed on the cell surfaces of many adenocarcinomas, particularly those originating from the gastrointestinal tract such as colon, gastric, and pancreatic cancers. The RAV12 monoclonal antibody specifically recognizes this glycotope. When bound by therapeutic antibodies like RAV12, targeting RAAG12 can modify growth factor-mediated signaling pathways within tumor cells and induce oncotic cell death. Clinical studies have shown that more than 90% of certain GI tumors express this antigen uniformly; however, some normal tissues—mainly mucosal or glandular/ductal epithelia—also display limited expression. Notably, adverse effects such as abdominal pain/diarrhea and transient liver enzyme elevations have been reported during clinical use of anti-RAGG12 therapies. These safety issues currently limit the maximum tolerated dose achievable for effective cancer treatment using this target.

Other names

RAAG12 antigenN-linked carbohydrate antigen recognized by RAV12Primate-restricted N-linked glycotope

Antibody-dependent cellular cytotoxicity via binding of RAV12 to RAAG12 on tumor cells; Induction of oncotic cell death in vitro and antitumor activity in xenograft models when targeted by RAV12 antibody